Latest News
-
Trade Setup: Nifty Continues Winning Streak Ahead of April F&O Expiry, Q4 Earnings In Focus -
Rs 10/Share Dividend: Record Date In Due Course; Buy The Banking Stock To Be Eligible? -
Stock Market Live Updates: Market Likely To Open With Minor Cuts; Nifty To Slide Below 22,400 -
Tech Mahindra Q4 Results Preview: Revenue May Fall, But Margins Seen To Expand; To Announce Dividend -
Rs. 7.75/Share Dividend: Record Date In Due Course; Buy The TATA Group Stock? -
Trade Call: Day Trading Stock Picks By Sumeet Bagadia of Choice Broking On Thursday, 25th April -
Swing Trading Guide: 3 Stock Picks By VLA Ambala On Thursday, 25th April -
HCL Tech Q4 Results, Dividend: EBIT Margins May Drop; Deal Wins, FY25 Guidance To Be Watched -
1:10 Split Coming Up: Crorepati FMCG ITC Turns Rs 1,50,000 To Rs 1.2 Crore; Makes Big Announcement; BUY? -
Biggest Ever Stock Splits, 49 New Shares On Existing 1 Share; FMCG Makes Big Announcement Before Splitting
Astrazeneca Loses 20 % In 2 Days;Trial On Covid Vaccine Candidate Halts
Shares in Astrazeneca cracked in Wednesday's (September 9, 2020) trade extending previous day's over 8% losses and lost 12% today.
This is after the pharma player was making consecutive gains but now the gains have been washed away as the likely Covid 19 vacccine candidate's last trial which was being worked upon in association with Oxford University has been stalled as there was seen an adverse reaction in one of the participant in the United Kingdom.
The company is now investigating if a report of a patient with a serious side effect is linked to the shot.
"Standard review process triggered a pause to vaccination to allow review of safety data", the company said in a statement on September 8, 2020.
The AstraZeneca-Oxford vaccine is viewed as the most effective vaccine against the deadly infection.
GoodReturns.in
